Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of
hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has …

Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor
positive breast cancers in the post-menopausal population. AI are often associated with …

The introduction of aromatase inhibitor (AI) therapy for the adjuvant treatment of
postmenopausal women with hormone receptor-positive breast cancer has led to a …

Aromatase inhibitors (AIs) have radically changed the prognosis of hormone receptor
positive breast cancer (BC) in post-menopausal women, and are a mainstay of the adjuvant …

Aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) were first recognized as a
distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole …

Objective To define the musculoskeletal syndrome associated with use of aromatase
inhibitors (AIs), specifically, to describe its incidence, time to onset, risk factors, and clinical …

Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with
hormone receptor-positive breast cancer. While the agents are associated with slightly …

Background Aromatase inhibitor induced musculoskeletal syndrome is experienced by
approximately half of women taking aromatase inhibitors, impairing quality of life and …

Abstract Background Aromatase inhibitors (AIs) are an effective treatment for
postmenopausal women with hormone receptor–positive breast cancer. However, patients …

In breast cancer patients, menopausal symptoms such as hot flashes, urogenital problems,
musculoskeletal symptoms and cognitive dysfunction are common, regardless of age at …